Global Vaccine Development Service Market Growth (Status and Outlook) 2025-2031

The global Vaccine Development Service market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Vaccine Development Service refers to the process of developing vaccines against various diseases. It involves the research, testing, and production of vaccines to prevent or treat specific infections or diseases. This service typically includes activities such as identifying target antigens, conducting preclinical studies, performing clinical trials, obtaining regulatory approvals, and scaling up production for widespread distribution. Vaccine development services are usually provided by pharmaceutical companies, research institutions, and government agencies to address public health needs and combat infectious diseases.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Vaccine Development Service Industry Forecast” looks at past sales and reviews total world Vaccine Development Service sales in 2024, providing a comprehensive analysis by region and market sector of projected Vaccine Development Service sales for 2025 through 2031. With Vaccine Development Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccine Development Service industry.

This Insight Report provides a comprehensive analysis of the global Vaccine Development Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Vaccine Development Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaccine Development Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccine Development Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccine Development Service.

This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine Development Service market by product type, application, key players and key regions and countries.

Segmentation by Type:
Therapeutic
Prophylactic
Other

Segmentation by Application:
Enterprise
Government

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
WuXi AppTec
Charles River Laboratories
Creative Biolabs
Creative Biostructure
PPD
Merck
Sartorius
Eurofins Scientific
Statens Serum Institut
Thermo Fisher Scientific
TRANSVAC
Azenta US

Please note: The report will take approximately 2 business days to prepare and deliver.